Frontier
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2021; 27(39): 6522-6526
Published online Oct 21, 2021. doi: 10.3748/wjg.v27.i39.6522
Acetyl-CoA carboxylase inhibitors in non-alcoholic steatohepatitis: Is there a benefit?
Georgios Neokosmidis, Evangelos Cholongitas, Konstantinos Tziomalos
Georgios Neokosmidis, Konstantinos Tziomalos, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki 54636, Greece
Evangelos Cholongitas, First Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens 11527, Greece
Author contributions: Neokosmidis G drafted the editorial; Cholongitas E and Tziomalos K critically revised the draft.
Conflict-of-interest statement: We have no conflict of interest to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Konstantinos Tziomalos, MD, MSc, PhD, Associate Professor, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 Stilponos Kyriakidi street, Thessaloniki 54636, Greece. ktziomalos@yahoo.com
Received: March 28, 2021
Peer-review started: March 28, 2021
First decision: June 14, 2021
Revised: June 28, 2021
Accepted: September 22, 2021
Article in press: September 22, 2021
Published online: October 21, 2021
Processing time: 205 Days and 16 Hours
Core Tip

Core Tip: Acetyl-CoA carboxylase inhibitors suppress de novo lipogenesis resulting in improvement in hepatic steatosis in both animal models and in patients with nonalcoholic fatty liver disease. However, the effects of these agents on hepatic fibrosis are inconsistent and they increase plasma triglyceride levels, casting doubt on their risk/ benefit profile.